Key clinical point: The rates of achieving low disease activity (LDA) and clinical remission were almost 20%-40% lower in patients with rheumatoid arthritis (RA) and elevated levels of adipocytokines.
Major finding: Patients in the highest vs lowest quartile of adiponectin (adjusted hazard ratio [aHR] 0.69) and leptin (aHR 0.77; both P < .05) had a significantly lower rate of achieving LDA. The odds of achieving clinical remission were lower in patients in the highest vs lowest quartile of adiponectin (aHR 0.69) and leptin (aHR 0.64; both P < .05).
Study details: This was an observational cohort study including 1274 veterans with RA and a disease activity score in 28 joints of >3.2.
Disclosures: This study did not declare any specific funding. JF Baker, BR England, and TR Mikuls reported receiving funding, grants, research support, or consulting fees from various sources.
Source: Baker JF et al. Adipocytokines and achievement of low disease activity in rheumatoid arthritis. Semin Arthritis Rheum. 2022;55:152003 (Apr 12). Doi: 10.1016/j.semarthrit.2022.152003